ACCURAY Incorporated Treats First Patients in New Zealand with CyberKnife System
January 30, 2023
Trending News 🌥️
ACCURAY ($NASDAQ:ARAY) Incorporated is a global leader in the field of radiation oncology. The company designs, manufactures and delivers innovative targeted radiation therapies for the treatment of cancer and other serious diseases. ACCURAY Incorporated recently announced that the first patients in New Zealand have been treated using the CyberKnife System, the world’s only robotic radiation therapy delivery device. The CyberKnife System is a revolutionary technology that tracks and adjusts for tumor motion in real-time, enabling clinicians to deliver high doses of radiation with sub-millimeter accuracy. This technology allows for more precise radiation delivery, which can be used to treat tumors anywhere in the body without the need for invasive surgery or anesthesia. This is an exciting breakthrough for cancer treatment in New Zealand as it enables clinicians to provide more accurate and effective radiation treatments. ACCURAY Incorporated is committed to providing leading-edge technology to benefit patients, and this new CyberKnife System will help New Zealand clinicians to do just that.
In addition, ACCURAY Incorporated is also developing a variety of imaging and software solutions to help improve cancer care. The company has a strong commitment to innovation and improving patient outcomes, and their products are helping to revolutionize cancer treatment around the world. With the introduction of the CyberKnife System to New Zealand, ACCURAY Incorporated is continuing its mission to make radiation therapy more accessible and effective for cancer patients everywhere.
Market Price
ACCURAY Incorporated, a leader in the field of radiation therapy and radiosurgery, is delighted to announce that the first patients in New Zealand have been treated with its CyberKnife System. On Wednesday, ACCURAY INCORPORATED stock opened at $2.4 and closed at $2.4. The CyberKnife System is a highly advanced and precise technology that delivers targeted radiation therapy to tumors anywhere in the body. This breakthrough technology can be used on tumors that are difficult to reach or are too small or too deep to treat with traditional radiation therapy. The CyberKnife System is non-invasive and can potentially spare healthy surrounding tissue from unnecessary radiation exposure.
The CyberKnife System is available at two hospitals in New Zealand, with plans for additional hospitals to come on board soon. ACCURAY Incorporated is proud to be a leader in the field of radiotherapy and radiosurgery and is committed to providing the highest quality of care to its patients. The company is excited to bring its revolutionary technology to New Zealand and looks forward to helping many more patients in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Accuray Incorporated. More…
| Total Revenues | Net Income | Net Margin |
| 418.96 | -9.77 | -2.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Accuray Incorporated. More…
| Operations | Investing | Financing |
| 6.25 | -4.53 | -18.73 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Accuray Incorporated. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 466.35 | 419.36 | 0.5 |
Key Ratios Snapshot
Some of the financial key ratios for Accuray Incorporated are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.5% | 53.1% | 0.4% |
| FCF Margin | ROE | ROA |
| 0.4% | 2.3% | 0.2% |
VI Analysis
Investors looking for a long-term investment should consider ACCURAY INCORPORATED, as the company’s fundamentals reflect its potential for growth. A quick analysis of the company’s financials on the VI app reveals a low health score of 3/10. This is due to its cashflows and debt, indicating that it is less likely to safely ride out any crisis without the risk of bankruptcy. However, ACCURAY INCORPORATED is strong in profitability, medium in asset, and weak in dividend and growth. The company is classified as an ‘elephant’, a type of company that is rich in assets when liabilities are taken into account. These qualities make it attractive to value investors and those looking for a safe bet in uncertain times, who are willing to take on a lower level of risk in exchange for lower returns. On the other hand, more aggressive investors may not find this company interesting due to its lack of high potential returns and its potential instability. Nevertheless, ACCURAY INCORPORATED is worth considering for those looking for a solid long-term investment with less risk. More…
VI Peers
There is fierce competition in the market for cancer treatment systems with Accuray Inc, Delcath Systems Inc, Bluejay Diagnostics Inc, and EBR Systems Inc all vying for a share. All of these companies have developed innovative treatments that are designed to improve patient outcomes.
– Delcath Systems Inc ($NASDAQ:DCTH)
Delcath Systems Inc is a medical device company that focuses on the treatment of cancer. The company’s market cap as of 2022 is 24.25M, and its ROE is -1466.9%. Delcath’s main product is a system that delivers chemotherapy to tumors while sparing healthy tissues. The company is based in New York City.
– Bluejay Diagnostics Inc ($NASDAQ:BJDX)
The company’s market cap is 14.63M as of 2022. The company’s ROE is -22.59%. The company is engaged in the development of diagnostic products for the early detection of cancer.
– EBR Systems Inc ($ASX:EBR)
EBR Systems Inc is a leading provider of innovative solutions for the treatment of cardiac arrhythmias. The company has a market cap of 126.85M as of 2022. EBR Systems Inc offers a variety of products and services to meet the needs of its customers. The company’s products include implantable cardioverter defibrillators, pacemakers, and other heart rhythm management devices. In addition, EBR Systems Inc provides services such as implantation, programming, and follow-up care.
Summary
Accuray Incorporated, a leader in the field of radiation oncology, recently treated its first patients in New Zealand using its CyberKnife System. This marks a significant milestone for the company and is a testament to its innovative technology. The future looks bright for the company as it continues to expand its reach and increase its focus on research and development. Investors should take note of this growing medical technology leader and consider adding Accuray to their portfolios.
Related Posts
Recent Posts
